Analysis of moxifloxacin in the treatment of 253 cases of stroke-associated pneumonia
Abstract
Objective To evaluate the efficacy of moxifloxacin in the treatment of stroke-associated pneumonia.Methods Moxifloxacin hydrochloride injection(400 mg/day) was administered intravenously for 3 to 7 days.The data of bacteriology and clinical efficacy were collected and analyzed.Results The clinical efficacy was confirmed in 95.3%of the 253 cases of stroke-associated pneumonia after moxifloxacin therapy.The bacterial clearance rate was 84.2%.Conclusions Moxifloxacin is one of the effective therapies for early stroke-associated pneumonia.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.